Companies: 10,795·Total market cap: $144.5T
Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc.

CERENASDAQHealthcare
$44.96
+$0.33(+0.74%)
Market Cap$8.2B
P/E Ratio
52W High$44.99
52W Low$19.59

Cerevel Therapeutics Holdings, Inc. (CERE) Shares Outstanding — Overview

Basic and diluted weighted average shares, YoY change, float context, and historical trend from SEC filings and FMP.

CERE · shares outstanding · updated Jun 9, 2026

Key metrics

Basic Shares Outstanding · Weighted average · fiscal year
162.1M +7.13% YoY Change
FY · as of Dec 31, 2023 · Reported in USD
vs 151.3M in FY 2022
Diluted Shares Outstanding
162.1M
incl. options, RSUs, convertibles
Dilution Spread
+0.00%
Diluted vs Basic
YoY Change
+7.13%
year-over-year
Float (Free Float)
77.8M
publicly tradable shares
42.7% of total
Source: FMP /income-statement · /shares-float · SEC 10-K / 10-QUpdated: 2026-06-09

Shares Outstanding Growth Rate

3-Year CAGRincreasing
+11.1%
2020 → 2023
5-Year CAGRincreasing
+18.1%
2018 → 2023
10-Year CAGR

Negative CAGR typically indicates share buyback or retirement activity. Interpret alongside Splits and Financials tabs. Splits / Financials

Shares outstanding history

↓ Decrease — typically buyback / retirement
↑ Increase — issuance / equity compensation
Latest
* most recent reported · FMP /income-statement · weightedAverageShsOut

Annual shares outstanding by year

FY 2023Latest
Diluted Shares: 162.1M
162.1M
+7.13%
FY 2022
Diluted Shares: 151.3M
151.3M
+10.76%
FY 2021
Diluted Shares: 136.6M
136.6M
+15.57%
FY 2020
Diluted Shares: 118.2M
118.2M
-7.04%
FY 2019
Diluted Shares: 127.1M
127.1M
+79.86%
FMP /income-statement · weightedAverageShsOut · weightedAverageShsOutDilUnit: Billions (B)

Healthcare sector shares outstanding comparison

Shares Outstanding for similar companies or competitors in the Healthcare sector.

#SymbolCompanyShares (Basic)vs CERE
#1
Merck & Co., Inc.MRK
Merck & Co., Inc.
2.502B+>999%
#2
Johnson & JohnsonJNJ
Johnson & Johnson
2.429B+>999%
#3
AbbVie Inc.ABBV
AbbVie Inc.
1.780B+998.6%
#4
AstraZeneca PLCAZN
AstraZeneca PLC
1.550B+856.5%
#5
UnitedHealth Group IncorporatedUNH
UnitedHealth Group Incorporated
910.0M+461.5%
#6
Eli Lilly and CompanyLLY
Eli Lilly and Company
898.0M+454.1%
#7
Cerevel Therapeutics Holdings, Inc.CERE
Cerevel Therapeutics Holdings, Inc.YOU
162.1M

/company-screener · per-peer /income-statement · cache 86400s

Understanding Shares Outstanding

What Are Shares Outstanding? (Basic)

Cerevel Therapeutics Holdings, Inc. (CERE) shares outstanding is the total number of issued shares held by shareholders — the basis for Basic EPS and market capitalization. As of December 31, 2023, Cerevel Therapeutics Holdings, Inc. reports 162.1M basic shares outstanding (weighted average).

Basic vs. Diluted Shares Outstanding

Cerevel Therapeutics Holdings, Inc.'s basic shares outstanding (162.1M) represents currently issued shares. Diluted shares outstanding (162.1M) also includes potential shares from stock options, RSUs, and convertibles. Dilution spread: +0.00%.

Shares Outstanding vs. Float (Free Float)

Cerevel Therapeutics Holdings, Inc.'s float is 77.8M (42.7% of total shares outstanding) — shares freely available for public trading, excluding insider-held and restricted shares.

Float77.8M(42.7%)
Outstanding182.2M

Float data from /shares-float reflects the most recent SEC filing period-end. The weighted average shares (from /income-statement) may differ — this is a normal reporting window difference, not a data error.

FMP /income-statement · /shares-float · SEC EDGAR · USD

About shares outstanding & methodology

Cerevel Therapeutics Holdings, Inc. (CERE) shares outstanding history from 2012 to 2023. Shares outstanding can be defined as the total number of shares held by all shareholders — including institutional investors, retail investors, and company insiders — assuming conversion of all convertible debt, securities, warrants, and options. This metric excludes the company's treasury shares.

Cerevel Therapeutics Holdings, Inc. shares outstanding for the fiscal year ending December 31, 2023 were 162.1M, a 7.13% increase year-over-year. Cerevel Therapeutics Holdings, Inc. FY 2023 shares outstanding were 162.1M, a +7.13% increase from FY 2022.

Cerevel Therapeutics Holdings, Inc. is a leading company operating in the Healthcare sector. The company's share count trajectory — with a 10-year CAGR of — — is a key signal for investors evaluating capital return policy, EPS accretion, and long-term shareholder value creation.

Figures tie to SEC 10-K/10-Q income statement disclosures and FMP /income-statement · /shares-float where noted.

Frequently asked questions

CERE shares outstanding · 4 questions

As of December 31, 2023, Cerevel Therapeutics Holdings, Inc. (CERE) has approximately 162.1M basic shares outstanding and 162.1M diluted shares outstanding. This represents a +7.13% year-over-year increase from FY 2022 (151.3M). The increase may reflect equity compensation issuances or secondary offerings.

CERE shares outstandinghow many shares does CERE haveCERE basic shares 2023CERE diluted shares

Data: FMP /income-statement · /shares-float · SEC EDGAR · weighted average basis · Cerevel Therapeutics Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: 2026-06-09